Oral LW402 for moderate-to-severe eczema
Part of Immune system & allergy, Skin clinical trials.
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had eczema for at least 1 year.
- Your eczema covers at least 10% of your body surface area (like your arms, legs, or trunk).
- Your eczema is scored as moderate or severe by a doctor using standard skin assessment tools.
- You are not allergic to drugs called JAK inhibitors.
- You do not have other autoimmune diseases (like lupus or inflammatory bowel disease) or other skin conditions that could interfere with eczema assessment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cream (CMS-D001) for people with moderate to severe eczema. Participants will receive either the study cream or a placebo (a cream with no active ingredient) to see if it helps reduce symptoms like itching and redness.
This trial tests an oral medication (capsule) for moderate to severe atopic dermatitis (eczema) that has not responded well to other treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
This study tests an oral medication (TLL-018) for people with moderate-to-severe atopic dermatitis (eczema) that hasn't been helped enough by topical treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.